PARP inhibitor Olaparib overcomes Sorafenib resistance through reshaping the pluripotent transcriptome in hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is one of the most common human malignancies worldwide with very poor prognosis. Resistance to targeted therapeutic drugs such as sorafenib remains one of the major challenges in clinical treatment. In the present study, PARP1 was found to be highly expressed in human...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Mol Cancer
Autori principali: Yang, Xiao-Dong, Kong, Fan-En, Qi, Ling, Lin, Jia-Xin, Yan, Qian, Loong, Jane Ho Chun, Xi, Shao-Yan, Zhao, Yue, Zhang, Yan, Yuan, Yun-Fei, Ma, Ning-Fang, Ma, Stephanie, Guan, Xin-Yuan, Liu, Ming
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2021
Soggetti:
Letter to the Editor
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7824946/
https://ncbi.nlm.nih.gov/pubmed/33485358
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12943-021-01315-9
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi